Find Funding Opportunities

The goal of this RFA is to enable partnerships between academics and companies that make wearable devices to validate their digital health technologies (DHTs) as digital monitoring biomarkers in ADRD populations. Applications will be required to optimize their DHTs in diverse patient populations from two or more early stage clinically diagnosed ADRD. Studies must demonstrate the accuracy of the digital markers to differentiate clinically meaningful features (such as sleep stage) and establish the longitudinal relationship between the features measured with quality-of-life metrics. Studies should also establish the relationship with one or more analytically validated ADRD biomarker(s) and standard cognitive assessments to validate the relationship between the features measured by the DHTs with the underlying pathophysiology or cognitive concept it reflects. An ideal outcome would be evidence for incorporating these DHT measures as monitoring biomarkers in future ADRD clinical trials. A 5-year phased mechanism is requested with a 2-year start-up phase (R61) to ensure adequate community engagement and recruitment of diverse patient populations, and to conduct pilot studies to optimize the algorithms; this will be followed by a 3-year R33 validation phase.

This Notice of Funding Opportunity (NOFO) invites applications for basic, translational, and clinical research projects that propose to study the role of environmental stress on the health inequities in Alzheimer’s Disease Related Dementias (ADRD), including Frontotemporal Dementia (FTD), Lewy Body Dementia (LBD), Vascular Contributions to Cognitive Impairment and Dementia (VCID), and Mixed-Etiology Dementia (MED). Environmental stressors include but are not limited to heat, crowding, air pollution, noise, violence, and psychosocial stress. Many of these environmental stressors are more prevalent in rural and urban disadvantaged communities which also have a higher risk for ADRD. Thus, there is a need to identify environmental stressors that impact health inequities in ADRD and to determine the mechanistic underpinnings of this stress. This NOFO will support mechanistic, translational, and human subject studies to understand the relationship between environmental stressors and health inequities in ADRD. It is expected that these studies will identify environmental stressors related to health inequities in ADRD and their clinical relevance. Ultimately, these studies should accelerate research towards better therapeutic interventions and quality of life.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint R25 program is to encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and clinical research workforce, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Mentoring Activities.The fully integrated educational activities should prepare undergraduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that either: 1) have a historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation NSF, see http://www.nsf.gov/statistics/wmpd/) (i.e., African Americans or Blacks, Hispanic or Latino Americans, American Indians, Alaska Natives, Native Hawaiians, U.S. Pacific Islanders, and persons with disabilities) or 2) have a documented track record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), which has resulted in increasing the institution's contribution to the national pool of graduates from underrepresented backgrounds who pursue biomedical research careers; b) a research-intensive institution that has an established neuroscience or neuroscience-related program; c) integrated

This Notice of Funding Opportunity Announcement (NOFO), issued by the National Institutes of Health (NIH) invites eligible United States small businesses to submit Small Business Technology Transfer (STTR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH awarding components identified in this NOFO are encouraged to submit STTR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). This Parent Funding Opportunity Announcement does not accept clinical trials.

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The NOFO aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services. Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R and D throughout the award. Clinical Trials are not accepted under this NOFO.

This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.

The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, postdoctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

The purpose of this Notice of Funding Opportunity (NOFO) is toinvite applications that aggregate and analyze existing data in the COVID-19 Neuro Databank-Biobank (NeuroCOVIDProject).TheNeuroCOVIDProject was establishedin 2020 to serve as a robust national resource to understand theneurological complicationsassociated with COVID-19 and the effects of COVID-19 on pre-existing neurological conditions. The NeuroCOVID Project has collected and curated a wide range of data from the United States and international sites. This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications ofCOVID-19 by using this de-identified database. Thedata may be combined with data from other U.S. and International databases for analyses.However,collection of new primary data from those affected by COVID-19 or comparison cohorts isNOT covered by this NOFO.

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

This NIH Neuroscience Development for Advancing the Careers of a Diverse Research Workforce (R25) is a flexible and specialized program designed to foster the development of neuroscience researchers from diverse backgrounds, including from underrepresented groups across career stages. Thus, it encourages applications from applicant organizations that propose innovative mentoring and professional development activities in the mission area(s) of the NINDS and/or NIMH. This Neuroscience Diversity R25 initiative will focus on factors that have been shown to affect retention of underrepresented graduate students, postdoctoral trainees, and junior faculty in neuroscience research such as mentoring, scientific networks, professional development, and attention to the structural and institutional environment regarding inclusion (http://acd.od.nih.gov/dbr.htm; Structure and Belonging: Pathways to Success for Underrepresented Minority and Women Ph.D. Students in STEM Fields; The Science of Effective Mentorship in STEMM).The NIH expects applicant institutions to propose programs that will lead to an improvement in the professional development, mentoring and technical expertise of individuals who are individuals from diverse backgrounds, including those from groups that are nationally underrepresented in neuroscience research. Programs that target transitions and/or more than one career stage for neuroscience career advancement and progression are strongly encouraged. This initiative will support the development of collaborative research education partnerships that will increase participants awareness and interest in the neurosciences, develop participants scientific knowledge and research skills that will allow them to progress and transition to more advanced neuroscience-related research education and training activities. Proposed program interventions to enhance workforce diversity in response to this FOA should also focus on asset models and leadership opportunities, rat